Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Decramer, G. Molenberghs, B. Celli, S. Kesten, D. Liu, D. Tashkin (Leuven, Belgium; Boston, Ridgefield, Los Angeles, United States Of America). Premature discontinuation during the UPLIFT study. Eur Respir J 2010; 36: Suppl. 54, 1189

Member's Comments

No comment yet.

Related content which might interest you: Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study Source: ERJ Open Res, 5 (1) 00175-2018; 10.1183/23120541.00175-2018 Year: 2019 Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Late Breaking Abstract - CPAP treatment in the very elderly with Ostructive Sleep Apnea. Pooled results from two multicenter randomized controlled trials Source: Virtual Congress 2021 – Sleep across the lifespan in the new era of COVID - 19 Year: 2021 Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial Source: Eur Respir J 2010; 35: 287-294 Year: 2010 Premature discontinuation of patients: a potential bias in COPD clinical trials Source: Eur Respir J 2007; 30: 898-906 Year: 2007 Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009 Safety of tiotropium in patients with cardiac events in the UPLIFT® trial Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Risk of non-lower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT trial Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Late Breaking Abstract - Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia – The BESTCILIA randomized placebo-controlled trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection Year: 2019 Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Fracture rate in patients with asthma receiving long-term early intervention with budesonide: the START study Source: Eur Respir J 2005; 26: Suppl. 49, 276s Year: 2005 Adherence to medication, mortality and severe exacerbations in the TORCH study Source: Annual Congress 2008 - COPD Year: 2008 NIV in postextubation outside clinical trials: Cohort study Source: Annual Congress 2010 - Noninvasive ventilation in the acute patient: outcome and pathophysiology Year: 2010 Do Beta-blockers Prevent Acute Exacerbations of COPD? – results of a randomized clinical trial Source: ERS Webinar 2019: Do Beta-blockers Prevent Acute Exacerbations of COPD? – results of a randomized clinical trial Year: 2019 Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Discontinuation rates of omalizumab treatment in a cohort of severe asthmatics in Bulgaria Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study Source: Eur Respir J, 56 (4) 2001935; 10.1183/13993003.01935-2020 Year: 2020 A double-blind, randomized, sham-controlled study of Targeted Lung Denervation in patients with moderate to severe COPD : AIRFLOW-2 One Year Outcomes Source: International Congress 2019 – Interventional pulmonology: a mixture of spices Year: 2019